22876-22-8

Basic information

• Product Name: 2-Mercapto-5-methylbenzoxazole
• Synonyms: SALOR-INT L470805-1EA;5-METHYL-2,3-DIHYDRO-1,3-BENZOXAZOLE-2-THIONE;5-METHYL-1,3-BENZOXAZOLE-2(3H)-THIONE;5-METHYLBENZOXAZOLINE-2-THIONE;2-MERCAPTO-5-METHYLBENZOXAZOLE;5-Methylbenzoxazoline-2-thione,97%;5-Methyl-2(3H)-benzoxazolethione, 97%;2-Mercapato-6-methylbenzoxazole
• CAS NO: 22876-22-8
• Molecular Formula: C₈H₇NOS
• Molecular Weight: 165.21
• Mol File: 22876-22-8.mol
• Article Data: 42

Chemical Properties

• Melting Point: 223-225°C
• Boiling Point: 260.9 °C at 760 mmHg
• Flash Point: 111.6 °C
• Appearance: /
• Density: 1.34 g/cm³
• Vapor Pressure: 0.0119mmHg at 25°C
• Refractive Index: 1.682
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 11.26±0.20(Predicted)
• Sensitive: Air Sensitive
• CAS DataBase Reference: 2-Mercapto-5-methylbenzoxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Mercapto-5-methylbenzoxazole(22876-22-8)
• EPA Substance Registry System: 2-Mercapto-5-methylbenzoxazole(22876-22-8)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 22876-22-8(Hazardous Substances Data)

Usage

General Description

2-Mercapto-5-methylbenzoxazole, also known as MMB, is a chemical compound with the molecular formula C8H7NOS. It is a benzoxazole derivative containing a mercapto group and a methyl group attached to the benzene ring. MMB is commonly used as a photoinitiator in the polymerization process and as a stabilizer in the presence of ultraviolet light. It is also utilized as an intermediate for the synthesis of various pharmaceutical and agrochemical products. Furthermore, MMB has shown potential as a corrosion inhibitor and a fluorescent probe for detecting metal ions. However, exposure to MMB should be limited, as it can be irritating to the skin, eyes, and respiratory system.

InChI:InChI=1/C8H7NOS/c1-5-2-3-7-6(4-5)9-8(11)10-7/h2-4H,1H3,(H,9,11)

Upstream product

• 22876-15-9 5-methylbenzo[d]oxazol-2(3H)-one 
• 140-89-6 potassium ethyl xanthogenate 
• 95-84-1 3-amino-4-hydroxytoluene 
• 75-15-0 carbon disulfide 
• 119-33-5 4-methyl-2-nitrophenol 
• 103-71-9 phenyl isocyanate 
• 103-72-0 phenyl isothiocyanate 
• 79558-90-0 N¹-methyl-N²-(2-hydroxy-5-methylphenyl)thiourea 
• 79558-91-1 N-(2-hydroxy-5-methylphenyl)-N'-phenylthiourea 
• 10531-78-9 5-methyl-1,3-benzoxazole 
• 137-26-8 Thiram 
• 128-04-1 sodium dimethyldithiocarbamate 

Downstream Products

• 38519-93-6 (5-methyl-benzooxazol-2-yl)-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine 
• 3770-60-3 2-chloro-5-methyl-1,3-benzoxazole 
• 811807-57-5 N-benzhydryl-2-(5-methyl-benzooxazol-2-ylsulfanyl)-acetamide 
• 439608-30-7 5-methyl-2-methylsulfanyl-benzooxazole 
• 199292-96-1 5-methyl-2-(4-methyl-1,4-diazepan-1-yl)benzoxazole 
• 445260-71-9 2-[(5-methylbenzo[d]oxazol-2-yl)thio]-N-(9H-fluoren-9-yl)acetamide 
• 1237542-35-6 2-(5-methyl-benzoxazol-2-yl)-sulfanyl-N-[4-(1-methyl-4,5-diphenyl-1H-imidazol-2-yl)phenyl]acetamide 
• 1334386-29-6 (S)-2-(2-hydroxy-5-methylphenylamino)-thiazoline-5,5-dimethyl-4-carboxylic acid methyl ester trifluoroacetate 
• 1334386-00-3 (S)-2-(2-hydroxy-5-methylphenylamino)-thiazoline-5,5-dimethyl-4-carboxylic acid 
• 1334386-01-4 (S)-2-(2-hydroxy-5-methylphenylamino)-thiazoline-5,5-dimethyl-4-carboxylic acid trifluoroacetate 
• 1352614-96-0 C₁₇H₁₅N₃O₃S 
• 1352614-97-1 C₁₇H₁₄ClN₃O₂S 
• 1352614-98-2 C₁₇H₁₄N₄O₄S 

Relevant articles and documents

Synthesis of benzoxazole associated benzothiazine-4-ones and their in vitro and in silico antimicrobial, antioxidant activities

In present study, a series of 3-[(5-methyl-1,3-benzoxazol-2-yl)amino]-2-phenyl-2,3-dihydro-4H-1,3-benzothiazin-4-ones (6a-n) were synthesized and elucidated by elemental, FT-IR, 1H & 13C NMR and LC-MS studies. The in vitro antibacter

HMOX1 inducers

The present invention is related to compounds of structure (I) as heme oxygenase 1 (HMOX 1) inducers. The present invention is also related a method of controlling the activity or the amount, or both the activity and the amount, of heme-oxygenase 1 in a mammalian subject. The definitions of the variables are provided herein.

Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR-2 inhibitors

Novel series of benzoxazoles 4a-f-16 were designed, synthesized, and evaluated for anticancer activity against HepG2, HCT-116, and MCF-7 cells. HCT-116 was the most sensitive cell line to the influence of the new derivatives. In particular, compound 5e was found to be the most potent against HepG2, HCT-116, and MCF-7 with IC50 = 4.13 ± 0.2, 6.93 ± 0.3, and 8.67 ± 0.5 μM, respectively. Compounds 5c, 5f, 6b, 5d, and 6c showed the highest anticancer activities against HepG2 cells with IC50 of 5.93 ± 0.2, 6.58 ± 0.4, 8.10 ± 0.7, 8.75 ± 0.7, and 9.95 ± 0.9 μM, respectively; HCT-116 cells with IC50 of 7.14 ± 0.4, 9.10 ± 0.8, 7.91 ± 0.6, 9.52 ± 0.5, and 12.48 ± 1.1 μM, respectively; and MCF-7 cells with IC50 of 8.93 ± 0.6, 10.11 ± 0.9, 12.31 ± 1.0, 9.95 ± 0.8, and 15.70 ± 1.4 μM, respectively, compared with sorafenib as a reference drug with IC50 of 9.18 ± 0.6, 5.47 ± 0.3, and 7.26 ± 0.3 μM, respectively. The most active compounds 5c-f and 6b,c were further evaluated for their vascular endothelial growth factor receptor-2 (VEGFR-2) inhibition. Compounds 5e and 5c potently inhibited VEGFR-2 at lower IC50 values of 0.07 ± 0.01 and 0.08 ± 0.01 μM, respectively, compared with sorafenib (IC50 = 0.1 ± 0.02 μM). Compound 5f potently inhibited VEGFR-2 at low IC50 value (0.10 ± 0.02 μM) equipotent to sorafenib. Our design was based on the essential pharmacophoric features of the VEGFR-2 inhibitor sorafenib. Molecular docking was performed for all compounds to assess their binding pattern and affinity toward the VEGFR-2 active site.